Compare Crispr Therapeutics AG (CRSP) vs Advanced Drainage Systems Inc (WMS) Price & Performance

CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% with bearish technical signals. The company shows negative profitability metrics including -$581.6M net income and -4,101.26% net margin for 2025, though revenue is expected to grow from $0 to $11M in 2026. Recent news highlights upcoming clinical data presentations and CASGEVY's commercial potential, with analyst consensus leaning bullish despite fundamental challenges.

The outlook remains speculative with significant cash burn but promising pipeline catalysts. Investment opportunity lies in gene-editing breakthroughs and CASGEVY adoption, while risks include sustained losses, clinical trial outcomes, and competitive pressure. Wall Street maintains a $67.83 price target, suggesting 30% upside if execution improves.

Advanced Drainage Systems (WMS) trades at $126.36, up 0.22% with a bearish technical signal despite strong fundamental performance. The company reported Q2 2026 EPS of $2.49, beating estimates by 18.6%, continuing a trend of earnings outperformance. Key financial metrics show robust profitability with 14% net income margin and 24.9% ROE, though cash flow turned negative in 2025 due to increased capital investments. Recent news highlights sustainability initiatives and institutional positioning changes.

WMS presents a compelling investment case with consistent earnings beats and strong analyst support ($188.70 price target), but faces near-term technical headwinds and cash flow pressures from aggressive expansion. The stock's current valuation at 21.5x P/E appears reasonable given growth prospects, though investors should monitor execution of NDS integration and capital allocation strategy.